Docality.com Logo
 
Dr. Arjun  Banerjee  Md image

Dr. Arjun Banerjee Md

320 Western Boulevard Building B
Glastonbury CT 06033
860 331-1008
Medical School: Case Western Reserve University School Of Medicine - 2002
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: Yes
License #: 043871
NPI: 1629021183
Taxonomy Codes:
207Q00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Arjun Banerjee is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:93306 Description:Tte w/doppler complete Average Price:$852.00 Average Price Allowed
By Medicare:
$232.92
HCPCS Code:77080 Description:Dxa bone density axial Average Price:$355.00 Average Price Allowed
By Medicare:
$68.91
HCPCS Code:G0180 Description:MD certification HHA patient Average Price:$130.00 Average Price Allowed
By Medicare:
$56.77
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$86.00 Average Price Allowed
By Medicare:
$20.75
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$171.00 Average Price Allowed
By Medicare:
$111.65
HCPCS Code:82306 Description:Vitamin d 25 hydroxy Average Price:$97.00 Average Price Allowed
By Medicare:
$41.94
HCPCS Code:69210 Description:Remove impacted ear wax Average Price:$102.00 Average Price Allowed
By Medicare:
$55.56
HCPCS Code:84443 Description:Assay thyroid stim hormone Average Price:$66.00 Average Price Allowed
By Medicare:
$23.80
HCPCS Code:94010 Description:Breathing capacity test Average Price:$81.00 Average Price Allowed
By Medicare:
$39.64
HCPCS Code:G0103 Description:PSA screening Average Price:$62.00 Average Price Allowed
By Medicare:
$26.06
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$109.00 Average Price Allowed
By Medicare:
$75.67
HCPCS Code:71020 Description:Chest x-ray Average Price:$65.00 Average Price Allowed
By Medicare:
$33.82
HCPCS Code:87086 Description:Urine culture/colony count Average Price:$42.00 Average Price Allowed
By Medicare:
$11.43
HCPCS Code:80061 Description:Lipid panel Average Price:$46.00 Average Price Allowed
By Medicare:
$15.74
HCPCS Code:83036 Description:Glycosylated hemoglobin test Average Price:$44.00 Average Price Allowed
By Medicare:
$13.75
HCPCS Code:G0438 Description:PPPS, initial visit Average Price:$203.00 Average Price Allowed
By Medicare:
$178.15
HCPCS Code:82728 Description:Assay of ferritin Average Price:$44.00 Average Price Allowed
By Medicare:
$19.30
HCPCS Code:80053 Description:Comprehen metabolic panel Average Price:$32.00 Average Price Allowed
By Medicare:
$11.30
HCPCS Code:82043 Description:Microalbumin quantitative Average Price:$27.00 Average Price Allowed
By Medicare:
$8.19
HCPCS Code:80076 Description:Hepatic function panel Average Price:$27.00 Average Price Allowed
By Medicare:
$8.67
HCPCS Code:80048 Description:Metabolic panel total ca Average Price:$29.00 Average Price Allowed
By Medicare:
$11.63
HCPCS Code:G0439 Description:PPPS, subseq visit Average Price:$136.00 Average Price Allowed
By Medicare:
$118.91
HCPCS Code:82570 Description:Assay of urine creatinine Average Price:$22.00 Average Price Allowed
By Medicare:
$7.33
HCPCS Code:85025 Description:Complete cbc w/auto diff wbc Average Price:$25.00 Average Price Allowed
By Medicare:
$11.02
HCPCS Code:87184 Description:Microbe susceptible disk Average Price:$23.00 Average Price Allowed
By Medicare:
$9.78
HCPCS Code:84550 Description:Assay of blood/uric acid Average Price:$17.00 Average Price Allowed
By Medicare:
$4.94
HCPCS Code:85027 Description:Complete cbc automated Average Price:$21.00 Average Price Allowed
By Medicare:
$9.17
HCPCS Code:85610 Description:Prothrombin time Average Price:$17.00 Average Price Allowed
By Medicare:
$5.56
HCPCS Code:Q2037 Description:Fluvirin vacc, 3 yrs & >, im Average Price:$25.00 Average Price Allowed
By Medicare:
$13.84
HCPCS Code:85007 Description:Bl smear w/diff wbc count Average Price:$15.00 Average Price Allowed
By Medicare:
$4.87
HCPCS Code:81003 Description:Urinalysis auto w/o scope Average Price:$12.00 Average Price Allowed
By Medicare:
$3.18
HCPCS Code:81002 Description:Urinalysis nonauto w/o scope Average Price:$12.00 Average Price Allowed
By Medicare:
$3.62
HCPCS Code:81001 Description:Urinalysis auto w/scope Average Price:$10.00 Average Price Allowed
By Medicare:
$4.48
HCPCS Code:G0009 Description:Admin pneumococcal vaccine Average Price:$31.00 Average Price Allowed
By Medicare:
$26.37
HCPCS Code:G0008 Description:Admin influenza virus vac Average Price:$31.00 Average Price Allowed
By Medicare:
$26.37
HCPCS Code:90471 Description:Immunization admin Average Price:$30.64 Average Price Allowed
By Medicare:
$26.18
HCPCS Code:90732 Description:Pneumococcal vaccine Average Price:$67.00 Average Price Allowed
By Medicare:
$63.99

HCPCS Code Definitions

93306
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
94010
Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
G0009
Administration of pneumococcal vaccine
G0008
Administration of influenza virus vaccine
G0103
Prostate cancer screening; prostate specific antigen test (psa)
G0180
Physician certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implementation of the plan of care that meets patient's needs, per certification period
Q2037
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
G0439
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit
G0438
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit
77080
Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)
71020
Radiologic examination, chest, 2 views, frontal and lateral
69210
Removal impacted cerumen requiring instrumentation, unilateral
90471
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1205807138
Cardiovascular Disease (Cardiology)
737
1457326787
Internal Medicine
549
1205800836
Ophthalmology
499
1396733895
Cardiovascular Disease (Cardiology)
430
1497971667
Orthopedic Surgery
410
1891794905
Cardiovascular Disease (Cardiology)
400
1669479994
Hand Surgery
287
1285692798
Orthopedic Surgery
265
1477539930
Diagnostic Radiology
254
1073588695
Cardiovascular Disease (Cardiology)
253
*These referrals represent the top 10 that Dr. Banerjee has made to other doctors

Publications

The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
(90)Y resin radioembolization is an emerging treatment in patients with liver-dominant metastatic neuroendocrine tumors (mNETs), despite the absence of level I data. The aim of this study was to evaluate the efficacy of this modality in a meta-analysis of the published literature.A comprehensive review protocol screened all reports in the literature. Strict selection criteria were applied to ensure consistency among the selected studies: human subjects, complete response data with time interval, resin microspheres, more than 5 patients, not a duplicate cohort, English language, and separate and complete data for resin-based (90)Y treatment of mNET if the study included multiple tumor and microsphere types. Selected studies were critically appraised on 50 study criteria, in accordance with the research reporting standards for radioembolization. Response data (Response Evaluation Criteria in Solid Tumors) were extracted and analyzed using both fixed and random-effects meta-analyses.One hundred fifty-six studies were screened; 12 were selected, totaling 435 procedures for response assessment. Funnel plots showed no evidence of publication bias (P = 0.841). Critical appraisal revealed a median of 75% of desired criteria included in selected studies. Very high between-study heterogeneity ruled out a fixed-effects model. The random-effects weighted average objective response rate (complete and partial responses, CR and PR, respectively) was 50% (95% confidence interval, 38%-62%), and weighted average disease control rate (CR, PR, and stable disease) was 86% (95% confidence interval, 78%-92%). The percentage of patients with pancreatic mNET was marginally associated with poorer response (P = 0.030), accounting for approximately 23% of the heterogeneity among studies. The percentage of CR and PR correlated with median survival (R = 0.85; P = 0.008).This meta-analysis confirms radioembolization to be an effective treatment option for patients with hepatic mNET. The pooled data demonstrated a high response rate and improved survival for patients responding to therapy.© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Splenomegaly-associated thrombocytopenia after hepatic yttrium-90 radioembolization. - Cardiovascular and interventional radiology
Thrombocytopenia is often observed after yttrium-90 radioembolization (RE). Possible mechanisms include radiation toxicity to the bone marrow, consumption in the liver due to local radiation effects, and sequestration in the spleen. We sought to identify the causative factors.Patients with complete baseline and 3-month post-RE imaging and laboratory data were included in this retrospective analysis. Univariate and multivariate regression analyses were performed on clinical, procedural, and imaging data.A total of 116 patients were identified (65 male, 51 female; median age 64 years). Forty-six patients were treated for primary and 70 for metastatic liver malignancy. Of these, 86 were treated with resin and 30 with glass microspheres; median activity was 1.85 GBq. Eighty-three patients underwent whole-liver treatment. Maximum individual change in platelet count was -20.2 % leading to new or increased grade of thrombocytopenia in 48 patients (41.4 %) by National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.02 criteria. Independent risk factors for decreased platelet count included change in spleen volume (median change +17.5 %; p = 0.001) and whole-liver (rather than lobar or segmental) treatment (p = 0.025). Administered activity and absorbed dose were not associated with change in platelet count. The change in spleen volume itself was associated with previous epidermal growth factor receptor-inhibitor treatment (p = 0.002), whole-liver absorbed dose (p = 0.027), and multiple-line chemotherapy (0.012) for whole-liver treatments only.Post-RE treatment increase of spleen volume is correlated with decreased peripheral platelet count suggesting a mechanism of increased portal hypertension and hypersplenism being responsible.
Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types. - European journal of nuclear medicine and molecular imaging
Fusion dual-tracer SPECT imaging enables physiological rather than morphological voxel-based partitioning and dosimetry for (90)Y hepatic radioembolization (RE). We evaluated its prognostic value in a large heterogeneous cohort of patients with extensive hepatic malignancy.A total of 122 patients with primary or secondary liver malignancy (18 different cell types) underwent SPECT imaging after intraarterial injection of (99m)Tc macroaggregated albumin (TcMAA) as a simulation of subsequent (90)Y microsphere distribution, followed by administration of an excess of intravenous (99m)Tc-labelled sulphur colloid (TcSC) as a biomarker for functional liver, and a second SPECT scan. TcMAA distribution was used to estimate (90)Y radiation absorbed dose in tumour (D T) and in functional liver. Laboratory and clinical follow-up were recorded for 12 weeks after RE, and radiographic responses according to (m)RECIST were evaluated at 3 and 6 months. Dose-response relationships were determined for efficacy and toxicity.Patients were treated with a median of 1.73 GBq activity of resin microspheres (98 patients) or glass microspheres (24 patients), in a whole-liver approach (97 patients) or a lobar approach (25 patients). The objective response rate was 41% at 3 months and 48% at 6 months. Response was correlated with D T (P < 0.01). Median overall survival was 10.1 months (95% confidence interval 7.4 - 12.8 months). Responders lived for 36.0 months compared to 8.7 months for nonresponders (P < 0.01). Stratified for tumour cell type, D T was independently associated with survival (P < 0.01). Absorbed dose in functional liver was correlated with toxicity grade change (P < 0.05) and RE-induced liver disease (P < 0.05).Fusion dual-tracer SPECT imaging offers a physiology-based functional imaging tool to predict efficacy and toxicity of RE. This technique can be refined to define dosing thresholds for specific tumour types and treatments, but appears generally predictive even in a heterogeneous cohort.
Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): Initial Results From a Prospective Multicenter Registry. - Chest
Systemic thrombolysis for acute pulmonary embolism (PE) carries up to a 20% risk of major bleeding, including a 2% to 5% risk of hemorrhagic stroke. We evaluated the safety and effectiveness of catheter-directed therapy (CDT) as an alternative treatment of acute PE.One hundred one consecutive patients receiving CDT for acute PE were prospectively enrolled in a multicenter registry. Massive PE (n = 28) and submassive PE (n = 73) were treated with immediate catheter-directed mechanical or pharmacomechanical thrombectomy and/or catheter-directed thrombolysis through low-dose hourly drug infusion with tissue plasminogen activator (tPA) or urokinase. Clinical success was defined as meeting all the following criteria: stabilization of hemodynamics; improvement in pulmonary hypertension, right-sided heart strain, or both; and survival to hospital discharge. Primary safety outcomes were major procedure-related complications and major bleeding events.Fifty-three men and 48 women (average age, 60 years [range, 22-86 years]; mean BMI, 31.03 ± 7.20 kg/m2) were included in the study. The average thrombolytic doses were 28.0 ± 11 mg tPA (n = 76) and 2,697,101 ± 936,287 International Units for urokinase (n = 23). Clinical success was achieved in 24 of 28 patients with massive PE (85.7%; 95% CI, 67.3%-96.0%) and 71 of 73 patients with submassive PE (97.3%; 95% CI, 90.5%-99.7%). The mean pulmonary artery pressure improved from 51.17 ± 14.06 to 37.23 ± 15.81 mm Hg (n = 92) (P < .0001). Among patients monitored with follow-up echocardiography, 57 of 64 (89.1%; 95% CI, 78.8%-95.5%; P < .0001) showed improvement in right-sided heart strain. There were no major procedure-related complications, major hemorrhages, or hemorrhagic strokes.CDT improves clinical outcomes in patients with acute PE while minimizing the risk of major bleeding. At experienced centers, CDT is a safe and effective treatment of both acute massive and submassive PE.ClinicalTrials.gov; No.: NCT01097928; URL: www.clinicaltrials.gov.
Technical and Anatomic Factors Influencing the Success of Inferior Vena Caval Stent Placement for Malignant Obstruction. - Journal of vascular and interventional radiology : JVIR
To evaluate the outcomes of inferior vena cava (IVC) stent placement for malignant obstruction and to identify anatomic and procedural factors influencing technical and clinical success.A total of 57 patients (37 male, 20 female; age range, 22-86 y) underwent 62 IVC stent placement procedures using 97 stents (47 Wallstents, 15 S.M.A.R.T. stents, 18 Wallflex stents, 17 others) from 2005 to 2016 for malignant IVC obstruction caused by hepatic metastases (n = 22; 39%), primary hepatic malignancy (n = 16; 28%), retroperitoneal metastases (n = 16; 28%), or other primary malignancy (n = 5; 9%). Presenting symptoms included lower-extremity edema (n = 54; 95%), ascites (n = 28; 50%), and perineal edema (n = 14; 25%). Sixteen percent (n = 10) and 10% (n = 6) of the procedures involved tumor and bland thrombus, respectively.Stent placements resulted in 100% venographic patency and significantly decreased pressure gradients (P < .0001). Lower-extremity swelling, perineal swelling, and abdominal distension improved within 7 days in 83% (35 of 42), 100% (9 of 9), and 40% (6 of 15) of patients, respectively, and at 30 days after the procedure in 86% (25 of 29), 89% (8 of 9), and 80% (4 of 5) of patients, respectively. Increased pre- and post-stent placement pressure gradients were associated with worse outcomes. A 4% stent misplacement rate (4 of 97) was related to the use of Wallstents with caudal stent tapering, asymmetric deployment superior to the obstruction, suprahepatic IVC involvement, and decreased stent adherence to the IVC wall as a result of local mechanical factors.Stent placement is reliable, rapid, and durable in improving malignant IVC syndrome. Understanding of technical and anatomic factors can improve accuracy and avoid complications of stent misplacement.Copyright © 2016 SIR. Published by Elsevier Inc. All rights reserved.

Map & Directions

320 Western Boulevard Building B Glastonbury, CT 06033
View Directions In Google Maps

Nearby Doctors

210 New London Tpke
Glastonbury, CT 06033
860 331-1543
49 Welles St Suite 211
Glastonbury, CT 06033
860 335-5246
330 Western Blvd
Glastonbury, CT 06033
860 462-2071
300 Hebron Ave Suite 113
Glastonbury, CT 06033
860 570-0764
55 Nye Rd
Glastonbury, CT 06033
860 214-4788
49 Welles St Suite 211
Glastonbury, CT 06033
860 335-5246
200C Oak Street
Glastonbury, CT 06033
860 578-8868
10 Commerce St Suite B
Glastonbury, CT 06033
860 309-9116
300 Hebron Ave Suite 211
Glastonbury, CT 06033
860 573-3668
379 Naubuc Ave
Glastonbury, CT 06033
860 523-3325